Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis

NCT06562803 · tracked via the Priya Life Science China tracker

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Phase

Not applicable

Started

2024-09-27

Last updated

2026-09-11

Condition(s) studied

Acute-On-Chronic Liver FailureSepsis

Investigational drug(s) / intervention(s)

double plasma cytokine adsorption system with sequential low-dose plasma exchangeplasma exchange

double plasma cytokine adsorption system with sequential low-dose plasma exchange: Both groups received comprehensive medical treatment, including antiviral therapy, anti-infection treatment, supportive care, symptomatic treatment, and prevention of complications. All patients will initiate ALSS within 48 hours of enrollment, with treatment administered every other day, for a total of three sessions. The experimental group： The first two sessions consisted of a double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE). This involved using a cytokine adsorption column (CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) and a bilirubin adsorption device (BS330,Jafron Biomedical Co., Ltd., Zhuhai, China) on the same treatment circuit. DPCAS treatment was performed first, with an adsorption volume of 4500ml to 5000ml over 2 to 3 hours, followed by plasma exchange (PE), with 1000ml of plasma and 500ml of 4% albumin being infused. The third treatment was plasma exchange, with the same dosing as in the control group.

plasma exchange: Based on comprehensive medical treatment, the control group received plasma exchange(PE) treatment, where whole blood was processed through a plasma separator (MICROPLAS MPS 07, BELLCO S.R.L., Italy), with a portion of the plasma discarded and replaced with 1000ml of plasma and 500ml of 4% albumin.Three sessions of plasma exchange (PE) performed every other day.

Study summary

This study aims to evaluate the efficacy and safety of the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) in patients with acute-on-chronic liver failure (ACLF) complicated by sepsis. The focus is on assessing the impact of the cytokine adsorption column(CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) on survival rates, inflammation markers, and organ function to determine its potential value in clinical practice.

The primary research questions are: (1) Does DPCAS+LPE artificial liver therapy improve the 4-week mortality rate in ACLF patients with sepsis? (2) Does it improve the 12-week mortality rate in these patients? Additionally, the study examines the effects of this therapy on APACHE II scores, SOFA scores, vasoactive-inotropic score, MELD scores, and COSSH-ACLF II scores, as well as the cytokine adsorption efficiency of the CA280.

Patients were randomly assigned to either the DPCAS+LPE group or the plasma exchange(PE) group. All patients received artificial liver therapy every other day, for a total of two sessions. Follow-up assessments were conducted before and after each therapy session, as well as at 1, 2, 3, 4, and 12 weeks.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: 1. Age between 18 and 70 years with a background of chronic liver disease, regardless of the presence of cirrhosis. 2. Total bilirubin (TBIL) \> 12 mg/dL. 3. International normalized ratio (INR) ≥ 1.5. 4. Meeting the diagnostic criteria for sepsis: confirmed or suspected infection, with a sequential organ failure assessment (SOFA) score increase of ≥ 2 points. (5) High inflammatory status: IL-6 \> 80 pg/ml. (6) Diagnosis of sepsis within the past 72 hours. Exclusion Criteria: 1. Inherited metabolic liver disease (including Wilson's disease, hereditary hemochromatosis, and alpha-1 antitrypsin deficiency). 2. Patients with hepatocellular carcinoma or other malignancies. 3. Pregnant or breastfeeding women. 4. Patients with human immunodeficiency virus (HIV) infection or other immunodeficiency diseases (including active hematological malignancies, congenital immunodeficiency syndromes, or those currently receiving high-dose systemic immunosuppressive therapy). 5. Unstable phase of cerebrovascular events. 6. History of organ transplantation. 7. Patients with irreversible or terminal extrahepatic organ failure that precludes safe extracorporeal circulation or confounds the intervention: ①Terminal chronic obstructive pulmonary disease, terminal cor pulmonale, brain death, or persistent vegetative state, or Grade IV hepatic encephalopathy. ②Requirement for renal replacement therapy (RRT) at the time of screening/enrollment. ③Despite adequate fluid resuscitation, vasopressors, and steroid treatment, unable to maintain mean arterial pressure above 65 mmHg. 8. Platelet count \< 50×10E9/L, severe coagulation disorders (INR\>3.5), or active bleeding. 9. Known allergies to extracorporeal circulation, hemoperfusion, or other severe allergic history. 10. Refusal by the patient or their legally authorized representative (LAR) to participate in the study, or sign the informed consent form. 11. Inability to return for regular follow-up visits as planned in the study. 12. Other conditions that, in the judgment of the researchers, make the patient unsuitable for enrollment.

Primary outcome measure(s)

Mortality rate — 4 weeks
4-week mortality rate

Trial sites (1)

Facility	City	Region	Status
Third Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong	Recruiting

More Third Affiliated Hospital, Sun Yat-Sen University trials in China

PRevention of OsTEoporotiC FracTure 2 Pilot Study Recruiting

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF Recruiting

Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure Active, not recruiting

Long-term Prognosis of Patients With Hepatitis B Related Acute-on-chronic Liver Failure Recruiting

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients Recruiting

Other trials for the same condition

PyroEVs/PLIN3 Mediate Lipid Droplet-Mitochondrial Coupling in Sepsis Endothelial Injury Recruiting

PCT Guided Antibiotics Use in Critically Ill Adult Patients in China Starting soon

Detection of Sepsis Occurrence by Using Blood Fluorescence Recruiting

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF Recruiting

Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06562803 on ClinicalTrials.gov ↗ ← All trials in China